Satralizumab

(Enspryng)

Satralizumab

Drug updated on 11/14/2023

Dosage FormInjection (subcutaneous: 120 mg/mL)
Drug ClassInterleukin-6 receptor antagonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.